SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Martinez Lage Pablo)
 

Sökning: WFRF:(Martinez Lage Pablo) > Involvement of the ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00011598naa a2200745 4500
001oai:DiVA.org:oru-115207
003SwePub
008240812s2024 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:159087621
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-1152072 URI
0247 a https://doi.org/10.1186/s12987-024-00555-32 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1590876212 URI
040 a (SwePub)orud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Delvenne, Auroreu Department of Psychiatry and Neuropsychology, Alzheimer Centrum Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands4 aut
2451 0a Involvement of the choroid plexus in Alzheimer's disease pathophysiology :b findings from mouse and human proteomic studies
264 1b BioMed Central (BMC),c 2024
338 a print2 rdacarrier
500 a The present study was supported by Alzheimer Nederland grant number WE.15‑2022‑01, the Research Foundation Flanders (FWO Vlaanderen; 1295223N, 1157621N and 1195019N), and partly supported by ZonMw (the Netherlands Organization for Health Research and Development) grant numbers 733050502 and 7330505021, an anonymous foundation and EMIF‑AD. The EMIF‑AD project has received support from the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement n° 115372, resources of which are composed of financial contribution from the European Union’s Seventh Framework Program (FP7/2007‑2013) and EFPIA companies’ in kind contribution.
520 a Background: Structural and functional changes of the choroid plexus (ChP) have been reported in Alzheimer's disease (AD). Nonetheless, the role of the ChP in the pathogenesis of AD remains largely unknown. We aim to unravel the relation between ChP functioning and core AD pathogenesis using a unique proteomic approach in mice and humans.Methods: We used an APP knock-in mouse model, APPNL-G-F, exhibiting amyloid pathology, to study the association between AD brain pathology and protein changes in mouse ChP tissue and CSF using liquid chromatography mass spectrometry. Mouse proteomes were investigated at the age of 7 weeks (n = 5) and 40 weeks (n = 5). Results were compared with previously published human AD CSF proteomic data (n = 496) to identify key proteins and pathways associated with ChP changes in AD.Results: ChP tissue proteome was dysregulated in APPNL-G-F mice relative to wild-type mice at both 7 and 40 weeks. At both ages, ChP tissue proteomic changes were associated with epithelial cells, mitochondria, protein modification, extracellular matrix and lipids. Nonetheless, some ChP tissue proteomic changes were different across the disease trajectory; pathways related to lysosomal function, endocytosis, protein formation, actin and complement were uniquely dysregulated at 7 weeks, while pathways associated with nervous system, immune system, protein degradation and vascular system were uniquely dysregulated at 40 weeks. CSF proteomics in both mice and humans showed similar ChP-related dysregulated pathways.Conclusions: Together, our findings support the hypothesis of ChP dysfunction in AD. These ChP changes were related to amyloid pathology. Therefore, the ChP could become a novel promising therapeutic target for AD.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng
653 a Alzheimer's disease
653 a Choroid plexus
653 a Cerebrospinal fluid
653 a Proteomics
653 a APP knock-in mice
653 a Amyloid-beta (A beta)
7001 a Vandendriessche, Charysseu VIB Center for Inflammation Research, VIB, Ghent, Belgium; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium4 aut
7001 a Gobom, Johanu Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden4 aut
7001 a Burgelman, Marliesu VIB Center for Inflammation Research, VIB, Ghent, Belgium; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium4 aut
7001 a Dujardin, Pieteru VIB Center for Inflammation Research, VIB, Ghent, Belgium; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium4 aut
7001 a De Nolf, Clintu Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium; Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium4 aut
7001 a Tijms, Betty M.u Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands4 aut
7001 a Teunissen, Charlotte E.u Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam University Medical Centers (AUMC), Amsterdam Neuroscience, Amsterdam, Netherlands4 aut
7001 a Schindler, Suzanne E.u Department of Neurology, Washington University School of Medicine, St. Louis, USA; Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, USA4 aut
7001 a Verhey, Fransu Department of Psychiatry and Neuropsychology, Alzheimer Centrum Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands4 aut
7001 a Ramakers, Inezu Department of Psychiatry and Neuropsychology, Alzheimer Centrum Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands4 aut
7001 a Martinez-Lage, Pablou Fundación CITA-Alzhéimer Fundazioa, San Sebastian, Spain4 aut
7001 a Tainta, Mikelu Fundación CITA-Alzhéimer Fundazioa, San Sebastian, Spain4 aut
7001 a Vandenberghe, Riku Neurology Service, University Hospitals Leuven, Louvain, Belgium; Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Louvain, Belgium4 aut
7001 a Schaeverbeke, Jolienu Neurology Service, University Hospitals Leuven, Louvain, Belgium; Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Louvain, Belgium4 aut
7001 a Engelborghs, Sebastiaanu Reference Center for Biological Markers of Dementia (BIODEM), Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium; Department of Neurology and Bru-BRAIN, Universitair Ziekenhuis Brussel, Brussels, Belgium; NEUR Research Group, Center for Neurosciences (C4N), Vrije Universiteit Brussel, Brussels, Belgium4 aut
7001 a De Roeck, Ellenu Reference Center for Biological Markers of Dementia (BIODEM), Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium; Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium4 aut
7001 a Popp, Juliusu Old Age Psychiatry, University Hospital Lausanne, Lausanne, Switzerland; Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatry University Hospital Zürich, Zurich, Switzerland4 aut
7001 a Peyratout, Gwendolineu Old Age Psychiatry, University Hospital Lausanne, Lausanne, Switzerland4 aut
7001 a Tsolaki, Magdau 1st Department of Neurology, AHEPA University Hospital, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, Makedonia, Thessaloniki, Greece4 aut
7001 a Freund-Levi, Yvonne,d 1956-u Örebro universitet,Institutionen för medicinska vetenskaper,Department of Neurobiology, Caring Sciences and Society (NVS), Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden; Department of Psychiatry in Region Örebro County and School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Department of Old Age Psychiatry, Psychology & Neuroscience, King’s College, London, UK4 aut0 (Swepub:oru)yfi
7001 a Lovestone, Simonu Johnson and Johnson Medical Ltd., Wokingham, UK; University of Oxford, Oxford, UK4 aut
7001 a Streffer, Johannesu Reference Center for Biological Markers of Dementia (BIODEM), Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium; H. Lundbeck A/S, Valby, Denmark4 aut
7001 a Bertram, Larsu Lübeck Interdisciplinary Platform for Genome Analytics, University of Lübeck, Lübeck, Germany4 aut
7001 a Blennow, Kaju Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France; Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC, Hefei, People’s Republic of China4 aut
7001 a Zetterberg, Henriku Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK; UK Dementia Research Institute at UCL, London, UK; Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China; Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison WI, USA4 aut
7001 a Visser, Pieter Jelleu Department of Psychiatry and Neuropsychology, Alzheimer Centrum Limburg, School for Mental Health and Neuroscience, Maastricht University, P.O. Box 616, Maastricht, 6200 MD, The Netherlands; Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands; Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Stockholm, Sweden4 aut
7001 a Vandenbroucke, Roosmarijn E.u VIB Center for Inflammation Research, VIB, Ghent, Belgium; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium4 aut
7001 a Vos, Stephanie J. B.u Department of Psychiatry and Neuropsychology, Alzheimer Centrum Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands4 aut
7102 a Department of Psychiatry and Neuropsychology, Alzheimer Centrum Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlandsb VIB Center for Inflammation Research, VIB, Ghent, Belgium; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium4 org
7730 t Fluids and Barriers of the CNSd : BioMed Central (BMC)g 21:1q 21:1x 2045-8118
8564 u https://doi.org/10.1186/s12987-024-00555-3y Fulltext
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-115207
8564 8u https://doi.org/10.1186/s12987-024-00555-3
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:159087621

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy